The new Modulus titanium implants are developed using additive manufacturing technology, or 3D printing, to create an organic, porous architecture that mimics the porosity and stiffness of bone for reduced stress shielding. By employing advanced microporous surface topography, Modulus XLIF creates an ideal environment for bone in-growth1. The device’s optimized architecture also leads to improved imaging characteristics compared to traditional titanium interbody devices.
“We’ve seen an increase in surgeon preference to use titanium interbody options in spine surgeries, and we were confident we could develop a titanium option that delivers the porous properties surgeons need,” said Matt Link, executive vice president of strategy, technology and corporate development of NuVasive. “Modulus XLIF maximizes the potential of 3D-printed spinal implants through the application of unique and advanced software optimization processes. This product launch further represents our continued commitment to advancing surgical materials, and delivering best-in-class implants that provide superior osseointegration and biomechanics.”
Modulus XLIF’s novel technology represents an advancement in the growing titanium interbody market. The implant expands the offerings used in the XLIF procedure, the only lateral approach spine procedure proven with over 15 years of clinical evidence and 400 peer-reviewed lateral-approach, XLIF specific publications.
“Surface architecture is an increasingly important part of the fusion process,” said Kade Huntsman, MD, orthopedic spine surgeon with the Salt Lake Orthopaedic Clinic in Salt Lake City, Utah. “The design of Modulus XLIF maximizes the potential of additive manufacturing through the combination of highly porous endplates with an optimized internal structure.”
NuVasive will showcase its market-leading, procedurally-integrated technologies, including the new Modulus XLIF in NuVasive Booth #713 at the North American Spine Society Annual Meeting held October 25-28, 2017 in Orlando, Fla.
NuVasive, Inc. (NASDAQ: NUVA) is transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1 Preclinical data on file. Data may not be representative of clinical results.
SOURCE NuVasive, Inc.